U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Medical Devices
  3. Products and Medical Procedures
  4. Respiratory Devices
  5. Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines
  1. Respiratory Devices

Recalled Philips Ventilators, BiPAP Machines, and CPAP Machines

Update: April 2024

On April 9, 2024, a federal district court entered a consent decree against Philips Respironics (Philips). The consent decree includes key provisions aimed to prioritize patient relief and ensure the company's regulatory compliance. The consent decree comes after Philips recalled certain ventilators, continuous positive airway pressure (CPAP) machines, and bi-level positive airway pressure (BiPAP) machines in June 2021 because of potential health risks—impacting 15 million devices worldwide. Patients impacted by the Philips recall remain a top priority for the agency as the FDA continues to take steps to protect the health and safety of individuals using these devices.

The consent decree includes provisions:

  • Requiring implementation of a Recall Remediation Plan, agreed to by the FDA and Philips, to help ensure relief is provided to patients impacted by the recall by way of receiving a new or reworked/remediated device, or for certain devices, providing the option for a partial refund.
  • Restricting, with limited exceptions, the production and sale of new CPAP machines, BiPAP machines, and other devices at several Philips Respironics facilities in Pennsylvania and California until certain requirements are met.

For more information, see the FDA's press release.

Español

In June 2021, Philips Respironics (Philips) recalled certain ventilators, bi-level positive airway pressure (also known as Bilevel PAP, BiPAP, or BPAP) machines, and continuous positive airway pressure (CPAP) machines because of potential health risks. The polyester-based polyurethane (PE-PUR) foam used in these devices to reduce sound and vibration can break down. If the foam breaks down, black pieces of foam, or certain chemicals that are not visible, could be breathed in or swallowed by the person using the device.

The problems reportedly associated with the PE-PUR foam breakdown could potentially result in serious injury and may require medical intervention to prevent permanent injury. The PE-PUR foam breakdown issue may result from exposure to hot and humid conditions and may be worsened by using ozone cleaners or other cleaning methods not recommended by the manufacturer.

On this page:

Related FDA pages

Recalled Devices

Philips recalled the following devices made between 2009 and April 26, 2021:

  • A-Series BiPAP A30
  • A-Series BiPAP A40 (ventilator)
  • A-Series BiPAP Hybrid A30
  • A-Series BiPAP V30 Auto (ventilator)
  • C-Series ASV (ventilator)
  • C-Series S/T and AVAPS
  • DreamStation
  • DreamStation ASV
  • DreamStation Go
  • DreamStation ST, AVAPS
  • Dorma 400
  • Dorma 500
  • E30
  • Garbin Plus, Aeris, LifeVent (ventilator)
  • OmniLab Advanced+
  • REMstar SE Auto
  • SystemOne ASV4
  • SystemOne (Q-Series)
  • Trilogy 100 (ventilator)
  • Trilogy 200 (ventilator)

Philips also recalled certain Trilogy Evo ventilators distributed from April 15, 2021 to May 24, 2021 with specific serial numbers.

Medical Device Recall Database Entries

Additional Resources

Questions?

For more information on Philips' recall notification, contact your local Philips representative or visit Philips' medical device recall information page.

More information on medical device recalls, including What is a Medical Device Recall, is available on FDA.gov.

If you have additional questions, contact the FDA's Division of Industry and Consumer Education (DICE).

 



Subscribe to CDRH Philips CPAP, BiPAP, and Ventilator Recall

Sign up to receive email updates about the CDRH Philips CPAP, BiPAP, and Ventilator Recall.

Back to Top